Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2024.09.1244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal Denervation: Antihypertensive Therapy or Gizmo Idolatry?
J Am Coll Cardiol
January 2025
Department of BioMedical Research, University of Bern, Bern, Switzerland. Electronic address:
Ultrasound renal denervation in hypertensive patients: A systematic review and meta-analysis.
PLoS One
January 2025
Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Introduction: Hypertension is the leading noncommunicable disease case affecting 1.28 billion individuals worldwide, with most cases located in low- and middle-income countries. While there are numerous techniques for treating mild to moderate hypertension, properly controlling severe or resistant hypertension poses substantial challenges.
View Article and Find Full Text PDFEffects of renal denervation on the course of cardiorenal syndrome: insight from studies with fawn-hooded hypertensive rats.
Physiol Res
December 2024
Department of Pathophysiology, The Second Faculty of Medicine, Charles University, Prague, Czech Republic, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Combination of chronic kidney disease (CKD) and heart failure (HF) results in extremely high morbidity and mortality. The current guideline-directed medical therapy is rarely effective and new therapeutic approaches are urgently needed. The study was designed to examine if renal denervation (RDN) will exhibit long-standing beneficial effects on the HF- and CKD-related morbidity and mortality.
View Article and Find Full Text PDF[Expert advisory on percutaneous renal denervation treatment of hypertension].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
The Paradise Renal Denervation System: An FDA-approved catheter-based treatment option for resistant hypertension.
Cardiol Rev
October 2024
From the Department of Medicine, New York Medical College, Valhalla, NY.
Resistant hypertension is defined as office blood pressure >140/90 mm Hg with a mean 24-hour ambulatory blood pressure of >130/80 mm Hg in patients who are compliant with 3 or more antihypertensive medications. Those who persistently fail pharmaceutical therapy may benefit from interventional treatment, such as renal denervation. Sympathetic nervous activity in the kidney is a known contributor to increased blood pressure because it results in efferent and afferent arteriole vasoconstriction, reduced renal blood flow, increased sodium and water reabsorption, and the release of renin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!